• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld Asia

BioWorld Asia

Feb. 23, 2021

View Archived Issues
Coronavirus vaccine, therapeutic illustration

China pushes on with vaccine efforts, with 16 candidates approved for trials

HONG KONG – China is steadily greenlighting more COVID-19 vaccines and drugs to go deeper into the clinic, giving the country a growing arsenal against the disease. To date, China’s National Medical Products Administration (NMPA) has approved a handful of drugs and 16 domestically developed COVID-19 vaccine candidates for trials, up from 11 in September 2020. Read More
Drug-vial-syringe

Clover bags $230M in series C, moves COVID-19 vaccine to phase II/III

Chengdu-based Sichuan Clover Biopharmaceuticals Inc., known for its Trimer-Tag technology, raised $230 million in a series C financing round. The proceeds will, most notably, help it advance its COVID-19 vaccine candidate, S-Trimer (SCB-2019), to a global phase II/III trial by June. Following its $43 million series B round in December 2019, Clover said on Tuesday, Feb. 23, that it raised more than $400 million in the last 12 months. The company uses its Trimer-Tag technology platform to produce covalently-trimerized fusion proteins to develop protein-based vaccines and biologic cancer therapies. Read More
Counterfeit COVID-19 vaccine vial

COVID-19 vaccine counterfeits set off alarms across the globe

CAJICA, Colombia – A cooler box with 70 vials allegedly filled with counterfeit COVID-19 vaccines seized from a Chinese couple in Colombia’s El Dorado International Airport on Feb. 17 underscored the growing challenges facing pharmaceutical companies, law enforcement authorities and health care regulators around the world. Patient safety, company liability, and the security of distribution channels have all been areas of growing concern. Read More
Brain clay model

Australian researchers identify potential treatment for fatal brain cancer in children

PERTH, Australia – The fight against diffuse intrinsic pontine glioma may finally see some progress, after experiments using 3D models of the tumor in animal studies showed that a combination therapy of the polyamine inhibitor AMXT-1501 (Aminex Therapeutics Inc.) and the ornithine decarboxylase 1 inhibitor difluoromethylornithine could eradicate cancer cells. Read More
Biotech deal illustration

Beigene strikes its second overseas deal this year with BITT for TNFR2 antibodies

HONG KONG – Beijing-based Beigene Ltd. struck its second deal outside China this year, signing an option and license agreement with Boston Immune Technologies & Therapeutics Inc. (BITT) for the latter’s tumor necrosis factor receptor 2 (TNFR2) antagonist antibodies. Read More
Antibiotics-petri-dish.png

Awaiting FDA decision on ibrexafungerp, Scynexis deals greater China rights to Hansoh

HONG KONG – Hansoh Pharmaceutical Group Co. Ltd. picked up the greater China rights to Scynexis Inc.’s lead candidate, ibrexafungerp. Hansoh will take charge of the development, regulatory approval and commercialization of the antifungal in exchange for a $10 million up-front payment and as much as $112 million in milestones. Read More

Ferring expands Mybiotics ties with deal for development of microbiota-based BV therapy

HONG KONG – Ferring Pharmaceuticals’ microbiome-focused subsidiary Rebiotix Inc. and Mybiotics Pharma Ltd. have agreed to a multiyear strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis. Read More
Vaccination

Australia establishes COVID-19 vaccine safety monitoring plan ahead of rollout

PERTH, Australia – With the first COVID-19 vaccine ready to be launched in Australia, the Therapeutic Goods Administration has released guidance on its pharmacovigilance plan to track real-world safety data and adverse events following immunization. Read More

Baby, it’s not as cold inside: Pfizer-Biontech submits new COVID-19 vaccine storage data

Pfizer Inc. and Biontech SE submitted new data to the FDA showing its COVID-19 vaccine’s stability can be maintained at temperatures often found in pharmaceutical freezers and refrigerators: -13°F to 5°F (-25°C to -15°C). Read More

Conference data for Feb. 16, 2021: ASCO Genitourinary Cancers Symposium

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology Genitourinary Cancers Symposium, including Astellas, Eisai, Merck, Seagen. Read More

Appointments and advancements for Feb. 23, 2021

New hires and promotions in the biopharma industry in Asia-Pacific, including: Aslan, Daiichi Sankyo, PYC. Read More

Financings for Feb. 23, 2021

Biopharmas in Asia-Pacific raising money in public or private financings, including: Molecular Templates, Regor, Sciwind, Takeda, Theravectys. Read More

In the clinic for Feb. 16-22, 2021

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Adagio, Algernon, Astellas, Bionomics, Biontech, Biophytis, Clene, Diffusion, Evgen, Gannex, Glaxosmithkline, Immunic, India Globalization Capital, Kintor, Kyowa Kirin, Mesoblast, Neuren, Novavax, Pfizer, PTC, Realta Life Sciences, Recce, Redhill, Sagent, Sanofi, Vtv. Read More

Other news to note for Feb. 23, 2021

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Abbvie, Aikido, Amyris, Athersys, Basilea, Beigene, Bial, Biohaven, Bionomics, Biontech, Boston Immune Technologies and Therapeutics, Cellular Biomedicine, Cend, China SXT, Eisai, Empathbio, Evolus, Glaxosmithkline, GT, Hansoh, Healios, Hikma, Huadong Medicine, Marinomed, Medytox, Moderna, Nascent, Neuren, Nicox, Novavax, Open Orphan, Pfizer, Provention, Qilu, Recce, Santen, Scynexis, Shenzhen Hepalink, SK Group, Vaxil Bio, Vir. Read More

Regulatory actions for Feb. 16-22, 2021

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Adamis, AIM Immunotech, Altimmune, Astellas, Astrazeneca, Beigene, Biontech, Celltrion, Curocell, Cytocom, Daiichi Sankyo, Dr. Reddy’s, Janssen-Cilag, JCR, Johnson & Johnson, Junshi, Pfizer, Pharmamar, RDIF, Seagen. Read More
Courts2.png

Regulatory front for Feb. 23, 2021

The latest global regulatory news, changes and updates affecting biopharma in Asia, including: Indoco Remedies, Takeda, Therapeutic Goods Administration, Torrent, U.S. Court of Appeals for the Federal Circuit. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe